Frontotemporal Dementia, Behavioral Variant: Clinical Trials

3 trials for Frontotemporal Dementia, Behavioral Variant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 recruiting. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 2, Recruiting 1

Follow Frontotemporal Dementia, Behavioral Variant: new trials by email Literature Review of Frontotemporal Dementia, Behavioral Variant trials Research Report on Frontotemporal Dementia, Behavioral Variant

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Vortioxetine - Fronto-temporal Dementia, Fronto-temporal Lobar Dementia
Phase 2RecruitingJohns Hopkins University502025-03-202026-03-09
Nabilone for Agitation in Frontotemporal Dementia
Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
Phase 2TerminatedSimon Ducharme, MD32023-03-072026-07-28
Intranasal Insulin in Frontotemporal Dementia (FTD)
Novolin-R insulin - Frontotemporal Dementia, Behavioral Variant
Phase 2TerminatedHealthPartners Institute32019-09-092023-10-27

Narrower conditions

Pick Disease of the Brain (3)  ·  Frontotemporal Dementia (2)  ·  Aphasia, Primary Progressive (1)  ·  Dementia (1)  ·  Insulin Resistance (1)  ·  Psychomotor Agitation (1)

Broader conditions

Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Frontotemporal Lobar Degeneration (3)  ·  Mental Disorders (3)  ·  Metabolic Diseases (3)  ·  Nervous System Diseases (3)  ·  Neurocognitive Disorders (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Dementia (2)  ·  Neurodegenerative Diseases (2)  ·  Proteostasis Deficiencies (2)  ·  TDP-43 Proteinopathies (2)  ·  Aberrant Motor Behavior in Dementia (1)  ·  Aphasia (1)  ·  Behavior (1)

Interventions

Insulin (1)  ·  Vortioxetine (1)  ·  nabilone (1)

Sponsors

HealthPartners Institute (1)  ·  Johns Hopkins University (1)  ·  Simon Ducharme, MD (1)

Countries

United States (2)  ·  Canada (1)

Top investigators

Christopher Morrow, MD (1)  ·  Michael H Rosenbloom, MD (1)

NIH funding

K23AG088248 (1)